| Alternative Names | B7-H3,B7 homolog 3 |
| Source | Human CD276(B7H3 2Ig) Protein; hFc Tag (GM-88590RP) is expressed from human 293 cells (HEK-293). It contains AA Leu 29 - Pro 245 (Accession # Q5ZPR3-2). This protein carries a hFc at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 49.3 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | CD276, also known as B7-H3 (2Ig isoform), is an immunoregulatory molecule that belongs to the B7 family of co-stimulatory proteins. It is encoded by the CD276 gene and is a type I transmembrane glycoprotein associated with the human immune system. CD276 protein was initially identified on antigen-presenting cells and later detected in various immune cell subsets, including T cells and NK cells, as well as in multiple solid tumor tissues. Unlike classic co-stimulatory molecules, CD276 exhibits dual functions: it can enhance T cell activation and cytokine production, but in the tumor microenvironment, it predominantly acts as a co-inhibitory molecule that suppresses T cell and NK cell-mediated anti-tumor immunity. T cells and NK cells are critical lymphocytes with essential roles in adaptive and innate immune responses, tumor surveillance, and cytokine secretion, making them central members of the immune system. Research indicates that CD276 protein plays a significant role in modulating immune tolerance, promoting tumor immune evasion, and regulating adaptive immune responses. Additionally, the overexpression of CD276 protein is associated with poor prognosis in various cancers, including non-small cell lung cancer and pancreatic cancer, as well as with inflammatory diseases and immune dysregulation, making it a promising therapeutic target for cancer immunotherapy, including antibody-drug conjugates (ADCs) and CAR-T cell therapies. |
| Alternative Names | B7-H3,B7 homolog 3 |
| Source | Human CD276(B7H3 2Ig) Protein; hFc Tag (GM-88590RP) is expressed from human 293 cells (HEK-293). It contains AA Leu 29 - Pro 245 (Accession # Q5ZPR3-2). This protein carries a hFc at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/μg, determined by LAL gel clotting assay |
| Predicted Mol Mass | 49.3 kDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | CD276, also known as B7-H3 (2Ig isoform), is an immunoregulatory molecule that belongs to the B7 family of co-stimulatory proteins. It is encoded by the CD276 gene and is a type I transmembrane glycoprotein associated with the human immune system. CD276 protein was initially identified on antigen-presenting cells and later detected in various immune cell subsets, including T cells and NK cells, as well as in multiple solid tumor tissues. Unlike classic co-stimulatory molecules, CD276 exhibits dual functions: it can enhance T cell activation and cytokine production, but in the tumor microenvironment, it predominantly acts as a co-inhibitory molecule that suppresses T cell and NK cell-mediated anti-tumor immunity. T cells and NK cells are critical lymphocytes with essential roles in adaptive and innate immune responses, tumor surveillance, and cytokine secretion, making them central members of the immune system. Research indicates that CD276 protein plays a significant role in modulating immune tolerance, promoting tumor immune evasion, and regulating adaptive immune responses. Additionally, the overexpression of CD276 protein is associated with poor prognosis in various cancers, including non-small cell lung cancer and pancreatic cancer, as well as with inflammatory diseases and immune dysregulation, making it a promising therapeutic target for cancer immunotherapy, including antibody-drug conjugates (ADCs) and CAR-T cell therapies. |
